MX2015009086A - Peptido. - Google Patents

Peptido.

Info

Publication number
MX2015009086A
MX2015009086A MX2015009086A MX2015009086A MX2015009086A MX 2015009086 A MX2015009086 A MX 2015009086A MX 2015009086 A MX2015009086 A MX 2015009086A MX 2015009086 A MX2015009086 A MX 2015009086A MX 2015009086 A MX2015009086 A MX 2015009086A
Authority
MX
Mexico
Prior art keywords
peptide
plp
seq
yeyli
gvlpwnafpgkvcgsnllsicktaefqm
Prior art date
Application number
MX2015009086A
Other languages
English (en)
Other versions
MX369413B (es
Inventor
David Wraith
Laurence Ordonez
Original Assignee
Apitope Int Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apitope Int Nv filed Critical Apitope Int Nv
Publication of MX2015009086A publication Critical patent/MX2015009086A/es
Publication of MX369413B publication Critical patent/MX369413B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response

Abstract

Se provee un péptido el cual es capaz de unirse a una molécula del MHC in vitro y de ser presentado a una célula T sin procesamiento del antígeno (es decir, un apítope), cuyo péptido comprende la totalidad o una porción de los siguientes péptidos de la proteína de proteolípidos: PLP 36-61: HEALTGTEKLIETYFSKNYQDY EYLI (SEQ ID NO. 1) PLP 179-206: TWTTCQSIAFPSKTSASIGSLCADARMY (SEQ ID NO. 2) PLP 207-234: GVLPWNAFPGKVCGSNLLSICKTAEFQM (SEQ ID NO. 3) se provee también el uso de dicho péptido en una composición farmacéutica, y un método para tratar y/o prevenir una enfermedad usando dicho péptido.
MX2015009086A 2013-01-15 2014-01-13 Peptido. MX369413B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1300683.8A GB201300683D0 (en) 2013-01-15 2013-01-15 Peptide
PCT/IB2014/058234 WO2014111841A2 (en) 2013-01-15 2014-01-13 Peptide

Publications (2)

Publication Number Publication Date
MX2015009086A true MX2015009086A (es) 2016-02-16
MX369413B MX369413B (es) 2019-11-07

Family

ID=47757994

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015009086A MX369413B (es) 2013-01-15 2014-01-13 Peptido.

Country Status (21)

Country Link
US (4) US20150352197A1 (es)
EP (1) EP2945965B8 (es)
JP (2) JP6407888B2 (es)
KR (1) KR102129763B1 (es)
CN (1) CN105102477B (es)
AU (1) AU2014206593B2 (es)
CA (2) CA3154542A1 (es)
DK (1) DK2945965T3 (es)
ES (1) ES2694660T3 (es)
GB (1) GB201300683D0 (es)
HK (1) HK1211595A1 (es)
HU (1) HUE040547T2 (es)
IL (1) IL239870B (es)
MX (1) MX369413B (es)
PL (1) PL2945965T3 (es)
PT (1) PT2945965T (es)
RU (1) RU2667428C2 (es)
SG (1) SG11201505530XA (es)
TR (1) TR201815667T4 (es)
WO (1) WO2014111841A2 (es)
ZA (1) ZA201504986B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7419229B2 (ja) * 2017-08-14 2024-01-22 百明信康生物技術（浙江）有限公司 方法
US20230172894A1 (en) 2020-05-06 2023-06-08 Imcyse Sa Combination treatment for fumarate-related diseases
BR112023024546A2 (pt) 2021-06-01 2024-02-15 Imcyse Sa Métodos de tratamento usando peptídeos imunogênicos

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6037135A (en) * 1992-08-07 2000-03-14 Epimmune Inc. Methods for making HLA binding peptides and their uses
US9340577B2 (en) * 1992-08-07 2016-05-17 Epimmune Inc. HLA binding motifs and peptides and their uses
WO1996032957A1 (en) * 1995-04-20 1996-10-24 Brigham & Women's Hospital Modulation of cytokine patterns of human autoreactive t-cell clones
WO1997035879A1 (en) * 1996-03-28 1997-10-02 Immulogic Pharmaceutical Corporation Myelin oligodendrocyte glycoprotein peptides and uses thereof
CA2425648A1 (en) * 2000-10-19 2002-04-19 Epimmune Inc. Hla class i and ii binding peptides and their uses
IL146016A0 (en) * 2001-10-17 2002-07-25 Yeda Res & Dev Synthetic peptides and dna sequences and compositions comprising them for treatment of multiple sclerosis
SG153871A1 (en) * 2004-06-25 2009-07-29 Id Biomedical Corp Quebec Compositions and methods for treating neurological disorders
US8188218B2 (en) * 2006-10-27 2012-05-29 University Of Kansas Bi-functional peptides for multiple sclerosis treatment and diagnosis
WO2012041867A2 (en) * 2010-09-27 2012-04-05 China Agricultural University Combined antigen and dna vaccine for preventing and treating autoimmune diseases

Also Published As

Publication number Publication date
HUE040547T2 (hu) 2019-03-28
PL2945965T3 (pl) 2019-08-30
KR20150107766A (ko) 2015-09-23
WO2014111841A2 (en) 2014-07-24
TR201815667T4 (tr) 2018-11-21
HK1211595A1 (en) 2016-05-27
CA3154542A1 (en) 2014-07-24
IL239870A0 (en) 2015-08-31
JP6407888B2 (ja) 2018-10-17
IL239870B (en) 2018-10-31
EP2945965B1 (en) 2018-07-25
PT2945965T (pt) 2018-11-14
WO2014111841A3 (en) 2014-10-30
CA2897894A1 (en) 2014-07-24
DK2945965T3 (en) 2018-11-19
EP2945965B8 (en) 2018-09-05
US20220016226A1 (en) 2022-01-20
AU2014206593A1 (en) 2015-07-23
AU2014206593B2 (en) 2017-09-07
RU2667428C2 (ru) 2018-09-19
CA2897894C (en) 2022-06-21
ZA201504986B (en) 2019-04-24
US20190275126A1 (en) 2019-09-12
CN105102477B (zh) 2019-03-19
GB201300683D0 (en) 2013-02-27
JP2016504412A (ja) 2016-02-12
JP2018193390A (ja) 2018-12-06
MX369413B (es) 2019-11-07
ES2694660T3 (es) 2018-12-26
CN105102477A (zh) 2015-11-25
US20150352197A1 (en) 2015-12-10
SG11201505530XA (en) 2015-08-28
RU2015134357A (ru) 2017-02-22
US20240148843A1 (en) 2024-05-09
EP2945965A2 (en) 2015-11-25
KR102129763B1 (ko) 2020-07-03

Similar Documents

Publication Publication Date Title
AR122964A2 (es) Péptidos útiles en la inmunoterapia contra el carcinoma hepatocelular (chc) y otros tipos de cáncer
CL2019003311A1 (es) Nuevos péptidos (seq id no:82) y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer epitelial de ovario y otros tipos de cáncer. (divisional solicitud 201800124)
PH12017501347A1 (en) Agonistic icos binding proteins
ZA201904725B (en) Personalised immunogenic peptide identification platform
PH12017500483A1 (en) Method for the absolute qualification of naturally processed hla-restircted cancer peptides
MX2017005344A (es) Composiciones y metodos para reforzar la eficacia de inmunoterapia celular adoptiva.
EP2528934A4 (en) AROMATIC-CATIONIC PEPTIDES AND USES THEREOF
MX2011011132A (es) Peptido auxiliar del antigeno del cancer.
IN2014KN01713A (es)
IN2014KN01716A (es)
IN2014KN01714A (es)
IN2015DN02349A (es)
IN2014CN04498A (es)
ES2625773T3 (es) Genómica de Actinoplanes utahensis
NZ594198A (en) Neil3 peptides and vaccines including the same
CL2019003426A1 (es) Nuevos péptidos (seq id n°174), combinaciones de péptidos y soportes para el uso en el tratamiento inmunoterapéutico de varios tipos de cáncer. (divisional solicitud 201800545)
NZ609916A (en) Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
EP4269562A3 (en) Antigen binding molecules and methods of use thereof
BR112017018703A2 (pt) peptídeo derivado de gpc3, composição farmacêutica para tratamento ou prevenção de câncer usando o mesmo, indutor de imunidade, e método para produzir células de apresentação de antígeno
MX2015009086A (es) Peptido.
EP2552462A4 (en) CCN3 PEPTIDES AND ANALOGS THEREOF FOR THERAPEUTIC USE
BR112017006969A2 (pt) peptídeo derivado de hsp70, composição farmacêutica para o tratamento ou a prevenção de câncer usando o mesmo, indutor de imunidade e método de produção de célula apresentadora de antígeno
PH12019502449A1 (en) Anti-jagged1 antigen binding proteins
MX369414B (es) Peptido.
MX2022008298A (es) Anticuerpo para sesgar proporciones de sexos y metodos de uso del mismo.

Legal Events

Date Code Title Description
FG Grant or registration